In the latest trading session, 3.44 million Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) shares changed hands as the company’s beta touched 1.69. With the company’s most recent per share price at $2.19 changing hands around $0.0 or 0.00% at last look, the market valuation stands at $126.08M. PRTK’s current price is a discount, trading about -66.67% off its 52-week high of $3.65. The share price had its 52-week low at $1.29, which suggests the last value was 41.1% up since then. When we look at Paratek Pharmaceuticals Inc.’s average trading volume, we note the 10-day average is 0.75 million shares, with the 3-month average coming to 540.68K.
Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) trade information
With action -0.90%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 17.11%, with the 5-day performance at -0.90% in the red. However, in the 30-day time frame, Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) is -0.90% down. Looking at the short shares, we see there were 2.64 million shares sold at short interest cover period of 6.74 days.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
Paratek Pharmaceuticals Inc. (PRTK) estimates and forecasts
Data shows that the Paratek Pharmaceuticals Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 59.85% over the past 6 months, a 32.48% in annual growth rate that is considerably higher than the industry average of 12.00%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Paratek Pharmaceuticals Inc. will rise 36.80%, while the growth in revenue is estimated to hit 66.70% for the next quarter. Year-over-year growth is forecast to reach 1.60% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of $38.82 million. 2 analysts are of the opinion that Paratek Pharmaceuticals Inc.’s revenue for the quarter ending Dec 2023 will be $52.78 million. The company’s revenue for the corresponding quarters a year ago was $30.21 million and $75.56 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 28.50%. The estimates for the next quarter sales put growth at -30.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.80%. The 2023 estimates are for Paratek Pharmaceuticals Inc. earnings to increase by 4.20%.
PRTK Dividends
Paratek Pharmaceuticals Inc. is expected to release its next quarterly earnings report in October.
Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.70% of Paratek Pharmaceuticals Inc. shares while 55.08% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 62.38%. There are 55.08% institutions holding the Paratek Pharmaceuticals Inc. stock share, with Nexpoint Asset Management, L.P. the top institutional holder. As of Jun 29, 2023, the company held 4.35% of the shares, roughly 2.5 million PRTK shares worth $5.52 million.
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 3.89% or 2.23 million shares worth $4.92 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Highland Fds II-Highland Global Allocation Fd and General American Investors Co. With 2.16 million shares estimated at $4.76 million under it, the former controlled 3.76% of total outstanding shares. On the other hand, General American Investors Co held about 3.21% of the shares, roughly 1.84 million shares worth around $4.07 million.
